Pfizer beat the expectation even though it fell short on revenue

By: Miguel A. Rodriguez

09:45, 14 September 2020

1595943842.jpg
Although it is in the race of developing a vaccine, Pfizer’s stock price fell in the first half of the year

For pharmaceutical giant Pfizer, the past quarter was busy as it is working on developing a COVID-19 vaccine, and the financial results that came in beat the expectations.

The net income fell for Q2 to $3.43 billion, meaning an EPS of 61 cents. During the same time last year, Pfizer had an EPS of 89 cents, and a net income of $5.05 billion.

It lost 11% on revenue, figures coming in at $11.80 billion, but it beat the $11.58 billion consensus. 

Pfizer provided guidance for the rest of the year. The EPS was adjusted to $2.85 with a $2.95 high from a previous $2.82 to $2.92. The revenue is expected to reach a high of $50.5 billion downgrading from an initial top of $50.6 billion.

During today’s pre-market session, the stock price gained 3.4%. Since the beginning of 2020, the share price fell 4.2%, while USA30 lost 6.9%.  

Sources: marketwatch.com

Share this article

The information presented herein is prepared by CAPEX.com/eu and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.                                                                                                                            Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience, or current financial situation.Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.

Most affected instruments

PFIZER

$ 10

USA30

$ 10